



INSTITUTIONAL BIOSAFETY COMMITTEE

Meeting Minutes

May 28, 2020
NBACC
NBACC 1st Floor Conference Room
11:30 am - 1:00 pm

Members Present:			Members Absent:	
B.J.	B.S.	A.H.	B.T.	
J.C.O.	B.H.	G.W.		
K.C.	B.C	L.H.		
G.H.	V.W.			
Guests Present: I.G.				
Prepared By: J.O. & K.B.				

1. Call to Order

1.1 B.J. called the meeting to order at 11:32 am.

2. Roll Call

2.1 A quorum was verified and I.G. was introduced as a guest PI present to answer questions concerning new IBC submission, IBC-20-0054.

3. Approval of Meeting Minutes

3.1. The February 2020 meeting minutes were reviewed and unanimously approved via email on February 21, 2020.

4. Ongoing Business

4.1. J.O. updated the committee on the status of the improvements to the registration amendment process and associated form. The new amendment form was changed to align with the new process of amendments being eligible for DMR, and the need for a new registration to be completed under certain amendment under certain conditions was eliminated. This form, along with the corresponding 081-001-SOP were put into the document control system.

5. New Business

5.1. The committee reviewed a new registration submission, IBC-20-0054. Prior to the meeting, B.J. sent an email to the committee regarding IBC registration regulations and whether NIH registration would be required of this new registration. Included in this email was a NIH document that provided guidance on studies that would not require registration with, or approval from NIH. The PI gave a summary of the project and answered questions that committee members had. After discussion, the committee determined that neither NIH

registration nor approval was required for the study, however A.H. suggested reaching out to NIH to confirm the IBC's decision to not register the project. The committee unanimously agreed on this correspondence with NIH. Based upon the discussion with the PI, a minor revision was made to the Biosafety Review portion of the registration. B.H. made a motion to approve the registration with that minor modification. B.C. seconded the motion and the committee unanimously approved. The IBC Registration is approved and work can commence while correspondence with NIH is occurring.

- 5.2. There were no Receipts of Recombinant Strains received.
- 5.3. There was one Etiologic Agent Registration that was received, #279. The committee had no questions or concerns.
- 5.4. The IBC Chair updated the committee on one exempt registration, IBC-20-0053, that was reviewed and deemed exempt on March 6, 2020.
- 5.5. The IBC Chair gave an update of amendments for IBC-18-0040, IBC-19-0043, and IBC-19-0046. These amendments were requests for personnel changes that were administratively approved on May 21, 2020.
- 5.6. The IBC Chair updated the committee regarding two registrations, IBC-18-0039 and IBC-19-0045, which were closed on May 21, 2020.

6. Training

- 6.1. N/A

7. Action Items

- 7.1. The Chair will send correspondence to NIH informing them of the committee's decision and reasoning to not register IBC-20-0054 with NIH.

8. Housekeeping Items

- 8.1. The next meeting is scheduled for Thursday, June 25, 2020, from 11:30 am -1:00 pm in the NBACC Building.

9. Adjourn

- 9.1 A motion was made by V.W. and seconded by G.H. to adjourn the meeting at 12:04 pm.

This work was funded under Agreement No. HSHQDC-15-C-00064 awarded to Battelle National Biodefense Institute by the Department of Homeland Security Science and Technology Directorate (DHS S&T) for the management and operation of the National Biodefense Analysis and Countermeasures Center a Federally Funded Research and Development Center. The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the U.S. Department of Homeland Security or the U.S. Government. The Department of Homeland Security does not endorse any products or commercial services mentioned in this presentation. In no event shall the DHS, BNBI or NBACC have any responsibility or liability for any use, misuse, inability to use, or reliance upon the information contained herein. In addition, no warranty of fitness for a particular purpose, merchantability, accuracy or adequacy is provided regarding the contents of this document.